Natco Pharma Limited has officially submitted its Annual Secretarial Compliance Report for the financial year ending March 31, 2026. The report, prepared by BK & Associates, Company Secretaries, confirms the company’s adherence to various SEBI regulations and corporate governance practices. The review covered statutory provisions, website disclosures, and related party transactions, finding overall compliance, with specific notes on certain related party transactions that were subsequently ratified.
Natco Pharma Files Annual Secretarial Compliance Report
Natco Pharma Limited has officially filed its Annual Secretarial Compliance Report for the financial year concluded on March 31, 2026. This report is a mandatory submission as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Independent Review Findings
The review was conducted by BK & Associates, Company Secretaries, who examined the company’s compliance with applicable statutory provisions and good corporate practices. The report, dated May 26, 2026, confirms that Natco Pharma Limited has complied with the specified regulations and guidelines throughout the review period. This includes adherence to the SEBI Act, SCRA, and various other SEBI regulations and circulars.
Key Compliance Areas
The review covered several critical areas of corporate governance and compliance, including:
- Adherence to Secretarial Standards.
- Adoption and timely updation of company policies.
- Maintenance and disclosures on the company’s website.
- Disqualification of directors.
- Details related to subsidiaries.
- Preservation of documents.
- Performance evaluation of the Board and Committees.
Related Party Transactions Noted
A specific observation was made regarding certain Related Party Transactions (RPTs) entered into without prior Audit Committee approval, to avail business opportunities. These transactions were subsequently ratified by the Audit Committee and the Board of Directors. Notable RPTs include:
- A transaction with NATCO Lifesciences Philippines Inc. for Rs. 22,14,515/-, ratified on May 28, 2025.
- A transaction with Natcofarma Do Brasil Ltda. for Rs. 1,45,51,508/-, ratified on November 14, 2025.
- A transaction with Adcock Ingram Holdings Limited for $31,383/-, ratified on March 24, 2026.
The report also confirms timely disclosures of events and information under Regulation 30 and compliance with the Prohibition of Insider Trading Regulations.
Scope and Limitations of the Review
BK & Associates emphasized that their responsibility was to report based on the examination of provided documents and information. The review is not an audit, and the correctness of financial records was not verified. The report serves the specific purpose of compliance with SEBI regulations and does not provide assurance on the company’s future viability or the efficacy of its management.
Source: BSE
